IL-12
Showing 1 - 25 of >10,000
Crohn Disease Trial in Calgary (TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 -
Not yet recruiting
- Crohn Disease
- TNFa Antagonist - Infliximab
- +5 more
-
Calgary, Alberta, CanadaUniversity of Calgary
Jun 22, 2023
Healthy Adult Trial in Melbourne (SON-1010 (IL12-FHAB))
Recruiting
- Healthy Adult
- SON-1010 (IL12-FHAB)
-
Melbourne, Victoria, AustraliaNucleus Network Pty Ltd
Oct 26, 2022
LAD1 Trial run by the NIAID (Ustekinumab)
Recruiting
- LAD1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Advanced Solid Tumor, Platinum-resistant Ovarian Cancer Trial (SON-1010)
Not yet recruiting
- Advanced Solid Tumor
- Platinum-resistant Ovarian Cancer
- SON-1010
- (no location specified)
Mar 10, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in
Withdrawn
- Anatomic Stage IV Breast Cancer AJCC v8
- +4 more
- Bintrafusp Alfa
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 2, 2022
HIV Trial in South Africa, United States (sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571)
Not yet recruiting
- HIV Infections
- sD-NP-GT8 DNA
- +4 more
-
Birmingham, Alabama
- +5 more
Mar 10, 2023
Cancer, Solid Tumor, Metastatic Checkpoint Refractory HPV Associated Malignancies Trial run by the National Cancer Institute
Recruiting
- Cancer
- +3 more
- Bintrafusp Alfa
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 11, 2022
Periodontitis Trial (No intervention was applied to the groups the samples will be collected in terms of the diagnosis (
Not yet recruiting
- Periodontitis
- No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)
- (no location specified)
Mar 31, 2022
Soft Tissue Sarcoma, Bone Sarcoma Trial in Houston (Cyclophosphamide, attIL2-T cells)
Not yet recruiting
- Soft Tissue Sarcoma
- Bone Sarcoma
- Cyclophosphamide
- attIL2-T cells
-
Houston, TexasM D Anderson Cancer Center
Nov 10, 2022
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer Trial run by the NCI (M7824, M9241, Stereotactic body radiation therapy
Recruiting
- Urothelial Cancer
- +4 more
- M7824
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Solid Tumors Trial in New York (procedure, drug, device, genetic)
Active, not recruiting
- Solid Tumors
- Production of Genetically-modified T cells
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Sep 1, 2022
Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma Trial in Birmingham (M032, Pembrolizumab)
Recruiting
- Glioblastoma Multiforme
- +2 more
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jan 30, 2023
Patients With Advanced Solid Tumors Trial in Beijing (human single chain IL-12 mRNA-single dose, human single chain IL-12
Recruiting
- Patients With Advanced Solid Tumors
- human single chain IL-12 mRNA-single dose
- human single chain IL-12 mRNA-multiple dose
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Jun 19, 2022
Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for
Not yet recruiting
- Primary Hepatocellular Carcinoma
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- camrelizumab for Injection
- (no location specified)
Nov 13, 2023
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck
Active, not recruiting
- Metastatic Head and Neck Squamous Cell Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Washington, District of Columbia
- +1 more
Mar 25, 2022
Behçet Disease Trial in Paris (Subcutaneous Ustekinumab)
Completed
- Behçet Disease
- Subcutaneous Ustekinumab
-
Paris, FranceHôpital Cochin, Department of Internal Medicine, National Refere
Nov 19, 2021
Sarcoma Trial in Beijing (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Recruiting
- Sarcoma
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
-
Beijing, ChinaPeking University People's Hospital
Nov 6, 2023
HIV-1-infection Trial in Los Angeles, San Francisco (PENNVAX-GP, INO-6145, INO-9012)
Completed
- HIV-1-infection
- PENNVAX-GP
- +3 more
-
Los Angeles, California
- +1 more
Apr 4, 2022
HIV Trial in Rochester, Philadelphia, Nashville (PENNVAX-B, IL-12 DNA plasmids)
Completed
- HIV Infections
- PENNVAX-B
- IL-12 DNA plasmids
-
Rochester, New York
- +2 more
Oct 13, 2021
Epithelial Tumors, Malignant, Epithelial Tumors, Malignant, Malignant Mesenchymal Tumor Trial run by the NCI (NHS-IL-12)
Completed
- Epithelial Neoplasms, Malignant
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 15, 2021
HIV Trial in United States (PennVax B, IL-12, IL-15)
Completed
- HIV Infections
- PennVax B
- +2 more
-
Birmingham, Alabama
- +7 more
Oct 13, 2021
Cervical Cancer, HPV Cancers, Anal Cancer Trial run by the NCI (PDS0101, M7824, NHS-IL12)
Active, not recruiting
- Cervical Cancer
- +4 more
- PDS0101
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Triple Negative Breast Cancer, Anthracycline-refractory TNBC Trial in Houston (Docetaxel, Pembrolizumab, IL-12 gene therapy)
Suspended
- Triple Negative Breast Cancer
- Anthracycline-refractory TNBC
- Docetaxel
- +2 more
-
Houston, TexasHouston Methodist Cancer Center
Mar 28, 2022
HIV Trial in United States (PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo)
Completed
- HIV Infections
- PENNVAX®-GP HIV-1 DNA vaccine
- +2 more
-
Decatur, Georgia
- +3 more
Oct 13, 2021